

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE FOURTH MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is issued by Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(1) of the Rules (the “**Listing Rules**”) Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposed to (i) make certain minor housekeeping amendments (the “**Proposed Amendments**”) to the third amended and restated memorandum of association and articles of association of the Company (the “**Existing Memorandum and Articles of Association**”); and (ii) adopt the fourth amended and restated memorandum of association and articles of association of the Company incorporating and consolidating all the Proposed Amendments (the “**Fourth Amended and Restated Memorandum and Articles of Association**”).

The Proposed Amendments and the adoption of the Fourth Amended and Restated Memorandum and Articles of Association are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting (the “**AGM**”) of the Company, and will become effective upon the approval by the Shareholders at the AGM. A circular of the Company containing detailed information of the Proposed Amendments as well as the adoption of the Fourth Amended and Restated Memorandum and Articles of Association together with a notice convening the AGM will be dispatched to the Shareholders in due course.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 28 March 2024

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Director, Mr Tao Ran, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.